This page is intended to provide access to U.S. Securities and Exchange Commission (SEC) filings for MapLight Therapeutics, Inc. (Nasdaq: MPLT), a clinical-stage biopharmaceutical company focused on central nervous system disorders. While no specific filings are listed in the available data here, as a Nasdaq-listed issuer MapLight has described an initial public offering and a concurrent private placement conducted under an effective registration statement filed with the SEC.
In general, SEC filings for a company like MapLight can include annual reports on Form 10-K, quarterly reports on Form 10-Q, and current reports on Form 8-K that describe material events such as clinical trial updates, financing transactions, or significant collaborations. Registration statements and prospectuses related to offerings, such as the IPO MapLight has referenced, also form part of the company’s regulatory record.
For a clinical-stage biopharmaceutical company, these filings typically discuss the status of product candidates like ML-007C-MA, ML-004, ML-021 and ML-009, outline clinical development plans, and describe risk factors related to central nervous system drug development. They may also provide details on research and development expenses, cash resources from offerings and private placements, and other financial information.
Stock Titan’s platform enhances access to such documents by pairing real-time updates from the SEC’s EDGAR system with AI-powered summaries. These tools are designed to help readers interpret lengthy filings, highlight key topics such as clinical trial disclosures, financing terms, and collaboration agreements, and locate information about insider transactions reported on Form 4 when available.
MapLight Therapeutics director Robert C. Malenka reported open‑market sales of 14,195 shares of Voting Common Stock to cover tax obligations tied to restricted stock unit settlements. The shares were sold between $18.00 and $19.15 per share across transactions on February 20–24, 2026, leaving him with 325,059 shares held directly. An additional 31,672 shares are held indirectly through the Robert C. Malenka Living Trust, for which he serves as sole trustee with voting and dispositive power, and these retained securities remain subject to a 180‑day IPO lock‑up agreement following the final prospectus dated October 26, 2025.
Robert Malenka, a director of MapLight Therapeutics, Inc. (MPLT), gave notice of a proposed sale of 736 common shares, with an aggregate market value of $13,354.72 and an approximate sale date of February 24, 2026. He acquired 736 shares on January 23, 2026 through restricted stock vesting under a registered plan.
The notice also lists prior common-share sales by Malenka dated January 28 through February 23, 2026, with individual amounts and gross proceeds.
MapLight Therapeutics, Inc. (MPLT) director Robert Malenka listed 11,264 common shares for sale, with an approximate sale date of February 23, 2026 and an aggregate market value of $207,490.76.
The shares were acquired from the issuer on January 23, 2026 through restricted stock vesting under a registered plan, with services rendered as payment. The recent-sales table lists, among other transactions, 21,262 shares sold January 29, 2026 for gross proceeds of $394,469.63 and 12,116 shares sold February 13, 2026 for gross proceeds of $220,685.67.
MapLight Therapeutics director George Pavlov bought 25,000 shares of Voting Common Stock in open-market transactions. The purchases occurred on February 18, 19, and 20, 2026, at weighted average prices of about $17.48, $17.57, and $17.86 per share, bringing his directly held stake to 25,000 shares.
For MapLight Therapeutics, Inc. (MPLT), Director Robert Malenka gave notice of a proposed sale of 2,195 common shares, with an approximate sale date of February 20, 2026, and an aggregate market value of $39,576.95. Morgan Stanley Smith Barney LLC is named as broker. The shares were acquired on January 23, 2026, through restricted stock vesting under a registered plan for services. The past-three-month sales table includes a February 13, 2026, sale of 12,116 shares for gross proceeds of $220,685.67.
MapLight Therapeutics director Robert C. Malenka reported an open‑market sale of 12,116 shares of Voting Common Stock to cover tax obligations tied to restricted stock unit settlements. The weighted average sale price was $18.21 per share, with individual trades ranging from $18.00 to $18.59.
After this transaction, he held 339,254 shares directly and 31,672 shares indirectly through the Robert C. Malenka Living Trust, where he serves as sole trustee with voting and dispositive power. Shares retained by him remain subject to a 180‑day lock‑up following the October 26, 2025 final prospectus for the company’s initial public offering.
T. Rowe Price Investment Management, Inc. has filed a Schedule 13G reporting beneficial ownership of 2,799,180 shares of MapLight Therapeutics Inc. common stock, representing 6.2% of the outstanding class as of the event date of 12/31/2025.
The firm indicates the shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of MapLight. It also expressly denies being the beneficial owner of the securities beyond what is reported in the filing.
Forbion Growth Opportunities Fund III Cooperatief U.A. and Forbion Growth III Management B.V. report a 7.1% beneficial ownership stake in MapLight Therapeutics, Inc. voting common stock. They beneficially own 3,226,400 shares with shared voting and dispositive power and no sole power over any shares. This percentage is based on 45,373,033 MapLight common shares outstanding as of November 24, 2025, as cited from the company’s Form 10-Q. Both reporting entities are organized in the Netherlands and file jointly on this Schedule 13G.
A shareholder of MPLT has filed a Rule 144 notice to sell 12,116 shares of common stock through Morgan Stanley Smith Barney LLC, with an indicated aggregate market value of 220,685.67. The issuer had 45,373,033 shares outstanding when this notice was prepared.
The shares to be sold were acquired on 01/23/2026 through vesting of restricted stock under a registered plan, treated as payment for services rendered. Over the prior three months, the same seller, Robert Malenka, completed several sales of MPLT common stock, including 21,262 shares on 01/29/2026 for gross proceeds of 394,469.63.
MapLight Therapeutics director Timothy John Garnett reported an open‑market purchase of Voting Common Stock on February 10, 2026. Through the Timothy J Garnett Revocable Trust, he bought 14,124 shares at a weighted average price of $17.89 per share, with individual trades between $17.76 and $17.90. Following this transaction, the trust holds 14,124 shares indirectly for him, and he also holds 49,525 shares directly.